Organvo报告24财年现金余额为1130万美元

2025-04-02 20:51

Organovo (NASDAQ:ONVO) said on Wednesday that its preliminary cash and cash equivalents balance was about $11.3M as of the end of the fiscal year on March 31, 2025.
Organovo’s preliminary net cash utilization during the fourth quarter from January 1, 2025 to March 31, 2025 was about $2.0M - $2.2M.
The company also clarified it expects to meet all requirements for continued listing on the Nasdaq Capital Market. Its common stock has closed above the $1.00 minimum bid price requirement since March 21, 2025 and believes it has met the minimum stockholder equity requirements of continued listing, pending Nasdaq confirmation.
Organovo further expects to receive a $5M milestone payment within the next 12 months associated with the anticipated start of a Phase 2 clinical trial for the FXR agonist that it recently sold. In connection with the sale of the FXR agonist, the company may receive future milestones of up to an aggregate of $50M, which is inclusive of the $5M milestone payment that would be received upon the commencement of a Phase 2 clinical trial.
Source: Press Release

More on Organovo Holdings